

Original Article

Prevalence of anemia in hemodialysis patients in Northwestern Libya

Mohamed Said¹ and Mahmoud Bashir J .Agena^{2,3}

1. Faculty of medical technology-Sabratha university

2. Libyan Biotechnology research center

3. Libyan Medical Research Center

Email: md.said15@gmail.com , mahmodagena@gmail.com

Abstract.

Background. Chronic kidney disease (CKD) is renal dysfunction leads to failure in the body's ability to maintain metabolic, fluid electrolytes, and balance. It mostly results in uremia or azotemia and can be classified into stages 1 to 5 based on the deterioration of glomerular filtration rate (GFR). These complications lead to the deficiency of erythropoietin (EPO) possible iron loss in patients on hemodialysis are considered the main factors in contributing anemia in CKD patients.

Aims: This study aims to evaluate the prevalence of anemia in CKD patients aged 18 years and above. **Methods:** A cross-sectional study was performed on 90 participants from patients with confirmed stage 5 of CKD who were on follow-up at the dialysis unit of Sabratha and Surman Hospitals.

Results: The prevalence of anemia in dialysis patients' was found to be extremely high as 97.8% (88/90), and the most effected patients belonged to age group 45-64 (54.4%). Interestingly, elderly (65-84) years old patients was the least affected group (17,8%) which also showed only one case of severe anemia (hemoglobin < 7 g/dl)

Conclusion: This study is strongly confirms the suggestions of anemia contributions in CKD patient spatially in late stages.

Recommendations: According to the high incidence of anemia among CKD patients, its highly recommended that routine hemoglobin checkups must be followed, and diet supplements might be required to replace the iron loose.

Keywords: Chronic kidney disease, erythropoietin, anemia, hemoglobin, iron loss, Sabratha.

Citation. Said Mohamed, Prevalence of anemia in dialysis patients in Northwestern of Libya
<https://doi.org/10.54361/ljmr.162b122023>

Received: 12/06/22accepted: 14/07/22; published: 31/12/23

Copyright ©Libyan Journal of Medical Research (LJMR) 2023. Open Access. Some rights reserved. This work is available under the CC BY license

<https://creativecommons.org/licenses/by-nc-sa/3.0/ig>

Introduction

Chronic kidney disease (CKD) is a progressive, irreversible deterioration of renal function in which the body's ability to maintain metabolic, fluid electrolyte, and balance fail, which results in uremia or azotemia. The National Kidney Foundation (NKF) and Kidney Disease Outcomes Quality Initiative (KDOQI) define CKD based on glomerular filtration rate (GFR) and divide the disease into five distinct stages (Agarwal, 2007). In Stage 1 CKD, the GFR is ≥ 90 ml/min/1.73 m². Stages 2, 3, and 4 CKD are defined by a GFR of 60–89 ml/min/1.73 m², 30–59 ml/min/1.73 m², and 15–29 ml/min/1.73 m², respectively. Stage 5 occurs when the GFR is < 15 ml/min/1.73 m² or when patients require dialysis (Akinsola et al, 2000 and Agarwal, 2007)

Complications of CKD included anemia, metabolic bone disease, metabolic acidosis, fluid and electrolyte imbalance, and uremia, which imposed a considerable burden on healthcare resources (Alemu et al, 2021), (Amoako, et al, 2014), (Annear et al, 2008) and (Bock et al, 2008).

Anemia is the commonest complication of CKD which accounts significant burden of cardiovascular diseases and the development of heart failure and stroke, which decreases the quality life of patients (Brookhart et al, 2008). Anemia occurs due to the reduction of kidney function which contributes to impaired physical activity, neurocognitive dysfunction, and poor quality of life (Annear et al, 2008) and

(Batchelor et al, 2020), (Cappellini et al 2017) and (Fishbane et al, 2017)

. Anemia in CKD is typically normocytic, normochromic, and hypoproliferative (Frazer et al, 2014). One of the kidney's functions is the production of erythropoietin, a signaling molecule that stimulates red blood cell production, in response to decreased oxygen levels in the blood (Goicoechea et al, 2005).

Disruption of this process may contribute anemia in CKD patients, a condition in which the number of circulating red blood cells, and therefore the level of hemoglobin, is lower than normal (Goicoechea et al, 2005).. Other possible causes of anemia in CKD patients include iron deficiency, inflammation, and the accumulation of uremic toxins (Hsu et al, 2002).

Therefore, the introduction of recombinant human erythropoietin and erythropoiesis-stimulating agents (ESA) have become the cornerstone of CKD anemia treatment and have reduced requirements for transfusion, improved the quality of life and reduced left ventricular hypertrophy and morbidity and mortality in CKD patients (Inker et al, 2019). Taken all the international guidelines, urologist should consider administration of ESA when the Hb level becomes < 11 g/dl in pre-dialysis patients and < 10 g/dl in dialysis patients (Jankowska et al, 2016). The present study aims to evaluate the prevalence of anemia in chronic kidney disease patients in

adults (>18 years of age) at a tertiary care hospital.

Methods

Study design.

A cross-sectional study was employed targeting patients with an established diagnosis of stage 5 CKD who were on follow-up at Nephrology clinic and hemodialysis unit of Sabratha and Surman Hospitals. An interviewer administered questionnaire was used to collect information from the patients who met the inclusion criteria. The study was carried out during the period from October to December 2022

Study Population Sabratha Teaching Hospital

This study comprised of 121 patients aged > 18 years and above whom attending the hemodialysis units in Surman and Sabratha hospitals and confirmed CKD stage 5. Only patients consented to take part in the study were included. However, 31 participants did not meet the minimum required data were excluded

Exclusion Criteria

1. Patients with known cause of anemia other than kidney disease
2. Pregnant women.
3. CKD non-dialysis

Statistical studies performed using graphPad Prism version 7. Ordinary Two-way ANOVA and P value 0.05 were chosen.

Results.

Socio-Demographic Characteristics of the Participants

In the present study, 90 participants were included. Out of these more than half, 53 (56.8%) of patients were males. The median age of the participants was 51.48, while the minimum and maximum ages of the patient were 18 and 83 years respectively.

Age groups:

The majority of participants were from age group 45-64 years old with a percentage of 51.1% which is more than half of the study samples, while age groups 18-44 and 65-84 were 31.1% and 17.8% respectively. The data are shown in figure1.




Figure 1: Age groups of dialysis patients attending Surman and Sabratha hospitals hemodialysis units, 2022 (N=90).

Gender groups:

while females presented by only about 41% (table 1).

Based on obtained data, out of 90 patients, 53 were males (about 59%)

Table 1: Gender distribution of dialysis patients attending Surman and Sabratha Hospitals hemodialysis unit, (N=90).

Gender	N	%
Male	53	58,9
Female	37	41,1
Total	90	100,0

According to the gender in each age group, patients aged between 45-64 years old were the most affected with 26 males and 20 females. However,

males appears to be more susceptible to disease than females in all age groups (figure 2).




Figure 2: the prevalence of gender type (male and female) in each age group.

Prevalence of anemia

Study participants' charts were reviewed to assess the prevalence of anemia, and the clinical characteristics of the respondents. Accordingly, from a total of 90 patients who were on follow-up hemodialysis units at Surman, and Sabratha hospitals, a total of 88 (97.8%) dialysis patients were found anemic.

The prevalence of anemia according to age was varied. Patient aged between 16-44 years old revealed 33.3% of total participants, while age group 45-64 were significantly a higher prevalence (54.4%) (P value 0.0196). However, the lowest prevalence was in age group (65-84).

Severity of anemia was categorized according to WHO criteria who defined the anemia status as: normal if hemoglobin is 13 g/dl or higher for men, and 12 g/dl or higher for women. mild anemia is hemoglobin 10 - 12.9 g/dl for men and 10 - 11.9 g/dl for women. moderate anemia is hemoglobin 7 - 9.9 g/dl for both genders. severe anemia is hemoglobin < 7 g/dl for both genders. However, the normal hemoglobin level was only

found in two cases one in age group 45-64 and the other in age group 65-84y.

Patients with mild anemia revealed 33.3% of all cases (30 cases). in which the majority of them were age group 45-64 years old 19 cases while other categories were approximately same on each age group.

Moderate anemia compromises the highest percentage of all participants with 49 cases which were 19, 22, and 8 cases in 16-44, 45-64, and 65-84 years old respectively.

The third part of anemia severity is severe anemia which the hemoglobin less than 7g/dl. In this study, the prevalence of severe anemia was the lowest compared to mild and moderate anemia with a total 9 cases. In details, the prevalence of anemia was similar in both age groups 16-44 and 45-64 years old with 4 cases in each group. However, only one case was recorded in the age group 65-84. The data demonstrated in figure 3. An overall prevalence of anemia in different age groups was analyzed and demonstrated in figure 3.




Figure 3: The prevalence of anemia in different age groups. The asterisks above the bars indicate significant differences ($P < 0.05$) between age group 45-64 and other groups (P value = 0.0196). The number of anemic and non-anemic patients according to anemia level is shown in figure 4. The most recorded category was among moderate level of anemia which was about half of participants.




Figure 4: Normal and anemic patients' analysis in different categories.

Discussion

Social-demographic characteristics

This study showed male predominance (58.9%) compared to female percentage (41.1%). This finding consistent with the findings of a study done in Ghana (Amoako et al, 2014). Studies done in Spain, USA and Nigeria also had higher male to female ratio (Goicoechea et al, 2005), (Ulasi et al, 2010). Male predominance could be a reflection of the fact that CKD and its risk factors such as hypertension, smoking, and alcoholism are common in males than females. The range of age was 16-83 years old, most of them were in middle age 45-64 years old with 46 cases out of 90 with percentage (51.1%), this age group considered economically active. These findings are consistent with findings from a study done in Ghana (Amoako et al, 2014).

Prevalence of anemia among renal failure patients

Recent findings has demonstrated a very high prevalence of anemia in end-stage CKD patients at Sabratha and Surman Hospitals with overall prevalence of 97.8%,

a finding similar to this was observed in two studies conducted in Tanzania whereby the prevalence was 92.4 % and 97% among 52 and 100 CKD patients (Kilonzo, 2010) and (Juma, 2012) respectively.

In addition, In India, Talwar et al, (2002) studied the hematological profile in 27 chronic renal failure patients and the prevalence of anemia was 94% of which 60% had microcytic hypochromic anemia with Serum ferritin low in 62%, low serum iron in 74% of the patients and bone marrow study revealed 57% of cases had

negative bone marrow iron store, (Talwar and Gupta, 2002).

However, it is higher than the reports made by other researchers that showed, Korea 44.9% (Kang et al, 2017), United States 15% (Stauffer and Fan, 2014) and Birhie, Ethiopia 53.5% (Birhie et al, 2021).

The high prevalence of anemia in the current study is because of differences in the definition of anemia, study population, and survey period. The variation of the prevalence may be due to differences in the methodology, variation of quality of care and quality of reporting, policy, and strategic differences.

It is also possible that the high prevalence of anemia might be explained partly by other causes peculiar to environment including poor nutrition and parasitic infestations.

The prevalence of ferritin and transferrin saturation among anemic patients.

The laboratory criteria used to define iron deficiency and provide indication for treatment are different in CKD compared to normal renal function (Cappellini et al, 2017). In CKD, absolute iron deficiency is likely to be present when the TSAT is $\leq 20\%$ and the serum ferritin concentration is ≤ 100 ng/mL among predialysis and peritoneal dialysis (PD) patients or ≤ 200 ng/mL among patients undergoing hemodialysis. By comparison, with normal kidney function, iron deficiency anemia is typically defined as serum ferritin concentrations < 30 ng/mL. Functional iron deficiency, both

ESA-induced functional deficiency and anemia of chronic disease are usually characterized by TSAT $\leq 20\%$ and elevated ferritin levels (as high as 800 ng/mL) (Cappellini et al, 2017). In this study, the 88 anemic patients were analyzed for the frequency of iron deficiency anemia using the previous criteria. The result shows that 45 patients (51.1%) of the total number had ferritin concentrations less than 200 ng/ml. This result is higher than that reported by Cases-Amenós et al, (2014) when 36.3% had an iron deficiency (ferritin < 100 ng/ml and/or TSAT $< 20\%$). The reason for that is they used different criteria to determine iron deficiency (ferritin < 100 ng/ml and/or TSAT $< 20\%$) (Cases-Amenós et al, 2014). However, the ferritin standard used in the current study is < 200 ng/ml and/or TSAT $< 20\%$.

Among 88 anemic patients in this study there were only 15 cases had TSAT level less than 20% with a percentage of 17% of the total number. This result is lower than that conducted in 2014 (Cases-Amenós et al, 2014), which revealed that the percentage of TSAT was 36.3%, that could be as a result of small number of participants 88 patients.

Conclusion

Results by recent study has demonstrated a very high prevalence of anemia in end-stage CKD patients at Sabratha and Surman Hospitals with

an overall prevalence of 97.8%, where the moderate degree of anemia is most frequent finding in both genders. In present study, 88 anemic patients were analyzed for the frequency of iron deficiency anemia. The result shows that 45 patients (51.1%) of total number had ferritin concentration less than 200 ng/ml. and only 15 cases has TSAT level less than 20% with percentage 17% of the total number.

Recommendations

There is a need for early diagnosis and treatment of anemia in CKD patients as anemia leads to CKD progression and cardiovascular disease in these patients.

As the mainstay treatment of anemia in CKD is ESAs and adequate iron storage are necessary to permit an optimal response, therefore it is highly recommended to do iron studies to establish types of iron deficiency as functional iron deficiency will need intravenous iron supplement compared to absolute iron deficiency **which needs oral iron.**

This was an university based study, therefore the results do not reflect true community picture, it is therefore recommended to perform a similar studies using large CKD sample size at the community level which would ascertain all stages of CKD and more factors related to anemia as in this 49 present study with high prevalence of anemia, only few factors were studied and skewed advanced CKD stage.

References

1. AGARWAL, R., 2007. Nonhematological benefits of

iron. *American Journal of Nephrology*, **27**(6), pp. 565-571.

2. AKINSOLA, A., DUROSINMI, M.O. and AKINOLA, N.O., 2000. The haematological profile of Nigerians with chronic renal failure. *African Journal of Medicine and Medical Sciences*, **29**(1), pp. 13-16.
3. ALEMU, B., TECHANE, T., DINEGDE, N.G. and TSIGE, Y., 2021. Prevalence of Anemia and Its Associated Factors Among Chronic Kidney Disease Patients Attending Selected Public Hospitals of Addis Ababa, Ethiopia: Institutional-Based Cross-Sectional Study. *International journal of nephrology and renovascular disease*, **14**, pp. 67-75.
4. AMOAKO, Y.A., LARYEA, D.O., BEDU-ADDO, G., ANDOH, H. and AWUKU, Y.A., 2014. Clinical and demographic characteristics of chronic kidney disease patients in a tertiary facility in Ghana. *The Pan African medical journal*, **18**, pp. 274.
5. ANNEAR, N.M.P., BANERJEE, D., JOSEPH, J., HARRIES, T.H., RAHMAN, S. and EASTWOOD, J.B., 2008. Prevalence of chronic kidney disease stages 3-5 among acute medical admissions: another opportunity for screening. *QJM : monthly journal of the Association of Physicians*, **101**(2), pp. 91-97.
6. ASHBY, D.R., GALE, D.P., BUSBRIDGE, M., MURPHY, K.G., DUNCAN, N.D., CAIRNS, T.D., TAUBE, D.H., BLOOM, S.R., TAM, F.W. and CHAPMAN, R.S., 2009. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. *Kidney international*, **75**(9), pp. 976-981.
7. BATCHELOR, E.K., KAPITSINOU, P., PERGOLA, P.E., KOVESDY, C.P. and JALAL, D.I., 2020. Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment. *Journal of the American Society of Nephrology : JASN*, **31**(3), pp. 456-468.
8. BOCK, H.A., HIRT-MINKOWSKI, P., BRÜNISHOLZ, M., KEUSCH, G., REY, S., VON ALBERTINI, B. and SWISS EFIXNES TRIAL INVESTIGATORS, 2008. Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/beta. *Nephrology Dialysis Transplantation*, **23**(1), pp. 301-308.
9. BROOKHART, M.A., SCHNEEWEISS, S., AVORN, J., BRADBURY, B.D., ROTHMAN, K.J., FISCHER, M., MEHTA, J. and WINKELMAYER, W.C., 2008. The effect of altitude on dosing and response to erythropoietin in ESRD. *Journal of the American Society of Nephrology : JASN*, **19**(7), pp. 1389-1395.
10. CAPPELLINI, M.D., COMIN-COLET, J., DE FRANCISCO, A., DIGNASS, A., DOEHNER, W., LAM, C.S., MACDOUGALL, I.C., ROGLER, G.,

- CAMASCHELLA, C. and KADIR, R., 2017. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. *American Journal of Hematology*, **92**(10), pp. 1068-1078.
11. Cases-Amenós, A., Martínez-Castelao, A., Fort-Ros, J., et al. 2014. Prevalence of anaemia and its clinical management in patients with stages 3–5 chronic kidney disease not on dialysis in Catalonia: MICENAS I study. *Nefrología*. **34**: 189–198
12. CASES, A., EGOICHEAGA, M.I., TRANCHE, S., PALLARÉS, V., OJEDA, R., GÓRRIZ, J.L. and PORTOLÉS, J.M., 2018. Anemia of chronic kidney disease: Protocol of study, management and referral to Nephrology. *Nefrología (English Edition)*, **38**(1), pp. 8-12.
13. CHANDRA, M., 1990. Pathogenesis of the anemia of chronic renal failure: The role of erythropoietin. *Nefrología*, **10**, pp. 12-22.
14. EISENGA, M.F., NOLTE, I.M., VAN DER MEER, P., BAKKER, S.J. and GAILLARD, C.A., 2018. Association of different iron deficiency cutoffs with adverse outcomes in chronic kidney disease. *BMC nephrology*, **19**(1), pp. 1-8.
15. EVANS, M., BOWER, H., COCKBURN, E., JACOBSON, S.H., BARANY, P. and CARRERO, J., 2020. Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis. *Clinical kidney journal*, **13**(5), pp. 821-827.
16. FEHR, T., AMMANN, P., GARZONI, D., KORTE, W., FIERZ, W., RICKLI, H. and WÜTHRICH, R.P., 2004. Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia. *Kidney international*, **66**(3), pp. 1206-1211.
17. FISHBANE, S., BLOCK, G.A., LORAM, L., NEYLAN, J., PERGOLA, P.E., UHLIG, K. and CHERTOW, G.M., 2017. Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia. *Journal of the American Society of Nephrology : JASN*, **28**(6), pp. 1851-1858.
18. FRAZER, D.M. and ANDERSON, G.J., 2014. The regulation of iron transport. *Biofactors*, **40**(2), pp. 206-214.
19. GOICOECHEA, M., DE VINUESA, S.G., GÓMEZ-CAMPDERÁ, F. and LUÑO, J., 2005. Predictive cardiovascular risk factors in patients with chronic kidney disease (CKD). *Kidney international*, **67**, pp. S35-S38.
20. HSU, C., MCCULLOCH, C.E. and CURHAN, G.C., 2002. Iron status and hemoglobin level in chronic renal insufficiency. *Journal of the American Society of Nephrology : JASN*, **13**(11), pp. 2783-2786.
21. INKER, L.A., GRAMS, M.E., LEVEY, A.S., CORESH, J., CIRILLO, M., COLLINS, J.F.,

- GANSEVOORT, R.T., GUTIERREZ, O.M., HAMANO, T. and HEINE, G.H., 2019. Relationship of estimated GFR and albuminuria to concurrent laboratory abnormalities: an individual participant data meta-analysis in a global consortium. *American journal of kidney diseases*, **73**(2), pp. 206-217.
22. JANKOWSKA, E.A., TKACZYSZYN, M., SUCHOCKI, T., DROZD, M., VON HAEHLING, S., DOEHNER, W., BANASIAK, W., FILIPPATOS, G., ANKER, S.D. and PONIKOWSKI, P., 2016. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. *European journal of heart failure*, **18**(7), pp. 786-795.
23. JUMA, A., 2012. **Prevalence of Anemia and its associated factors in patients with Chronic Kidney Disease at Muhimbili National Hospital Dar es Salaam**, (Doctoral dissertation, Muhimbili University of health and Allied Sciences).
24. KANG, E., HAN, M., KIM, H., PARK, S.K., LEE, J., HYUN, Y.Y., KIM, Y.S., CHUNG, W., KIM, H.J., OH, Y.K., AHN, C. and OH, K.H., 2017. Baseline General Characteristics of the Korean Chronic Kidney Disease: Report from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD). *Journal of Korean medical science*, **32**(2), pp. 221-230.
25. KAUTZ, L., JUNG, G., VALORE, E.V., RIVELLA, S., NEMETH, E. and GANZ, T., 2014. Identification of erythroferrone as an erythroid regulator of iron metabolism. *Nature genetics*, **46**(7), pp. 678-684.
26. KILONZO, K.G., *CHRONIC RENAL FAILURE AND ASSOCIATED RISK FACTORS AMONG MEDICAL ADMISSIONS AT KCMC, MOSHI*, .
27. LOCATELLI, F., BÁRÁNY, P., COVIC, A., DE FRANCISCO, A., DEL VECCHIO, L., GOLDSMITH, D., HÖRL, W., LONDON, G., VANHOLDER, R. and VAN BIESEN, W., 2013. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. *Nephrology Dialysis Transplantation*, **28**(6), pp. 1346-1359.
28. MACDOUGALL, I.C., BOCK, A., CARRERA, F., ECKARDT, K., GAILLARD, C., VAN WYCK, D., ROUBERT, B., CUSHWAY, T., ROGER, S.D. and FIND-CKD STUDY INVESTIGATORS, 2014. The FIND-CKD study—a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale. *Nephrology Dialysis Transplantation*, **29**(4), pp. 843-850.
29. MCGONIGLE, R.J., WALLIN, J.D., SHADDUCK, R.K. and FISHER, J.W., 1984. Erythropoietin deficiency and

- inhibition of erythropoiesis in renal insufficiency. *Kidney international*, **25**(2), pp. 437-444.
30. MCMURRAY, J., PARFREY, P., ADAMSON, J.W., ALJAMA, P., BERNS, J.S., BOHLIUS, J., DRÜEKE, T.B., FINKELSTEIN, F.O., FISHBANE, S. and GANZ, T., 2012. Kidney disease: Improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. *Kidney International Supplements*, , pp. 279-335.
31. MINUTOLO, R., LOCATELLI, F., GALLIENI, M., BONOFILIO, R., FUIANO, G., OLDRIZZI, L., CONTE, G., DE NICOLA, L., MANGIONE, F. and ESPOSITO, P., 2013. Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics. *Nephrology Dialysis Transplantation*, **28**(12), pp. 3035-3045.
32. MORENO, F., GOMEZ, J., JOFRE, R., VALDERRABANO, F., GONZALEZ, L. and GORRIZ, J., 1996. Nephrology dialysis transplantation quality of life in dialysis patients. *A Spanish multicentre study.NDT*, **11**(Suppl 2), pp. 125-129.
33. NATIONAL COLLABORATING CENTRE FOR CHRONIC CONDITIONS (GREAT BRITAIN), 2006. Anaemia management in chronic kidney disease: national clinical guideline for management in adults and children, 2006, Royal College of Physicians.
34. NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE, 2015. Chronic kidney disease: managing anaemia. *NICE guideline (NG8)*, .
35. NISSENSON, A.R., WADE, S., GOODNOUGH, T., KNIGHT, K. and DUBOIS, R.W., 2005. Economic burden of anemia in an insured population. *Journal of managed care pharmacy*, **11**(7), pp. 565-574.
36. PALMER, S.C., SAGLIMBENE, V., MAVRIDIS, D., SALANTI, G., CRAIG, J.C., TONELLI, M., WIEBE, N. and STRIPPOLI, G.F., 2014. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. *Cochrane Database of Systematic Reviews*, (12),.
37. PEYSSONNAUX, C., ZINKERNAGEL, A.S., SCHUEPBACH, R.A., RANKIN, E., VAULONT, S., HAASE, V.H., NIZET, V. and JOHNSON, R.S., 2007. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). *The Journal of clinical investigation*, **117**(7), pp. 1926-1932.
38. PORTOLÉS, J., GORRIZ, J.L., RUBIO, E., DE ÁLVARO, F., GARCÍA, F., ALVAREZ-CHIVAS, V., ARANDA, P. and MARTINEZ-CASTELAO, A., 2013. The development of

- anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney disease. *BMC nephrology*, **14**(1), pp. 1-9.
39. RAMBOD, M., KOVESDY, C.P. and KALANTAR-ZADEH, K., 2008. Combined high serum ferritin and low iron saturation in hemodialysis patients: the role of inflammation. *Clinical journal of the American Society of Nephrology : CJASN*, **3**(6), pp. 1691-1701.
40. RAO, M., WONG, C., KANETSKY, P., GIRNDT, M., STENVINKEL, P., REILLY, M. and RAJ, D., 2007. Cytokine gene polymorphism and progression of renal and cardiovascular diseases. *Kidney international*, **72**(5), pp. 549-556.
41. RATCLIFFE, L.E., THOMAS, W., GLEN, J., PADHI, S., PORDES, B.A., WONDERLING, D., CONNELL, R., STEPHENS, S., MIKHAIL, A.I. and FOGARTY, D.G., 2016. Diagnosis and management of iron deficiency in CKD: a summary of the NICE guideline recommendations and their rationale. *American Journal of Kidney Diseases*, **67**(4), pp. 548-558.
42. ROTTEMBOURG, J., KADRI, A., LEONARD, E., DANSAERT, A. and LAFUMA, A., 2011. Do two intravenous iron sucrose preparations have the same efficacy? *Nephrology Dialysis Transplantation*, **26**(10), pp. 3262-3267.
43. SARGENT, J.A. and ACCHIARDO, S.R., 2004. Iron requirements in hemodialysis. *Blood purification*, **22**(1), pp. 112-123.
44. SMITH, R.E.J., 2010. The clinical and economic burden of anemia. *The American Journal of Managed Care*, **16 Suppl Issues**, pp. S59-66.
45. STACK, A.G., ALGHALI, A., LI, X., FERGUSON, J.P., CASSERLY, L.F., CRONIN, C.J., REDDAN, D.N., HUSSEIN, W. and ELSAYED, M.E., 2018. Quality of care and practice patterns in anaemia management at specialist kidney clinics in Ireland: a national study. *Clinical kidney journal*, **11**(1), pp. 99-107.
46. STAUFFER, M.E. and FAN, T., 2014. Prevalence of anemia in chronic kidney disease in the United States. *PloS one*, **9**(1), pp. e84943.
47. SUEGA, K., BAKTA, M., DHARMAYUDHA, T.G., LUKMAN, J.S. and SUWITRA, K., 2005. Profile of anemia in chronic renal failure patients: comparison between predialyzed and dialyzed patients at the Division of Nephrology, Department of Internal Medicine, Sanglah Hospital, Denpasar, Bali, Indonesia. *Acta medica Indonesiana*, **37**(4), pp. 190-194.
48. TALWAR, V.K., GUPTA, H.L. and SHASHINARAYAN, 2002. Clinicohaematological profile in chronic renal failure. *The Journal of the Association of Physicians of India*, **50**, pp. 228-233.
49. TSUBAKIHARA, Y., GEJYO, F., NISHI, S., IINO, Y., WATANABE, Y., SUZUKI,

- M., SAITO, A., AKIBA, T., HIRAKATA, H. and AKIZAWA, T., 2012. High target hemoglobin with erythropoiesis-stimulating agents has advantages in the renal function of non-dialysis chronic kidney disease patients. *Therapeutic Apheresis and Dialysis*, **16**(6), pp. 529-540.
50. TSUBAKIHARA, Y., GEJYO, F., NISHI, S., IINO, Y., WATANABE, Y., SUZUKI, M., SAITO, A., AKIBA, T., HIRAKATA, H. and AKIZAWA, T., 2012. High target hemoglobin with erythropoiesis-stimulating agents has advantages in the renal function of non-dialysis chronic kidney disease patients. *Therapeutic Apheresis and Dialysis*, **16**(6), pp. 529-540.
51. ULASI, I.I. and IJOMA, C.K., 2010. The enormity of chronic kidney disease in Nigeria: the situation in a teaching hospital in South-East Nigeria. *Journal of tropical medicine*, **2010**.
52. VAN SWELM, R.P., WETZELS, J.F. and SWINKELS, D., 2020. The multifaceted role of iron in renal health and disease. *Nature Reviews Nephrology*, **16**(2), pp. 77-98.
53. WALTERS, D., KAKIETEK, J., DAYTON EBERWEIN, J. and SHEKAR, M., 2017. An investment framework for meeting the global nutrition target for anemia. *World Bank Group, Washington, DC, USA*, .
54. WENGER, R.H. and HOOGEWIJS, D., 2010. Regulated oxygen sensing by protein hydroxylation in renal erythropoietin-producing cells. *American Journal of Physiology-Renal Physiology*, **298**(6), pp. F1287-F1296.
55. YI, S., MOON, S.J. and YI, J., 2019. Low-normal hemoglobin levels and anemia are associated with increased risk of end-stage renal disease in general populations: A prospective cohort study. *PloS one*, **14**(4), pp. e0215920.
56. AHEMIÏ, K., 2012. KDIGO clinical practice guideline for anemia in chronic kidney disease. *Kidney international*, **2**, pp. 279.